Move to topTop
February 09, 2022

TOKYO, JAPAN - February 9, 2022 - Terumo Corporation (TSE: 4543) today announced that in conjunction with the new 5-Year Growth Strategy with a 10-Year Vision (GS26) starting next fiscal year, the company will implement a new Executive Officers' Management System effective from April 1, 2022 onwards. This new management system will redefine the responsibilities of both the Executive Officers representing the entire Terumo Group and the Executive Officers representing Terumo Corporation.

The current Executive Officers' Management System was implemented in 2002 with its structure built mainly around the headquarter in Japan . Since then, Terumo has rapidly expanded its business globally. The new Executive Officers' Management System will play a part to enhance Terumo Group's competitiveness on a global level and to achieve our visions defined in GS26.

The changes implemented in the new Executive Officers' Management System is as follows.

1. Establishment of Group Executive Officer (GEO)

Group Executive Officers will be responsible to set management directions and to discuss Terumo Group management strategies beyond business divisions and regions.

The GEO will be structured around Directors and Executive Officers such as the Chairman of the Board, the President and CEO, Company Presidents, Corporate Function Executives, CEOs of Major Business Subsidiaries, and Regional Representatives.

Furthermore, among the GEO structure, the Group Managing Executive Officer (GMEO) will take part in the Executive Management Meeting (EMM) as a core member to execute management strategies for the Terumo Group. By definition, the GMEOs must be a Managing Executive Officer/Senior Managing Executive Officer or higher.

2. Redefinition of Executive Officer (EO)

Executive Officers are those who are not part of GEO and is responsible for making decisions for their Company or Function.

In addition, the new Executive Officers' Management System clarifies each members' job description based on their position and responsibility. Appointment of each Executive Officer will be based on this clarified criteria and process. For Terumo Corporation in Japan, positions above managers will also implement the same methodology and approach.

With the new Executive Officers' Management System taking place, Terumo will strive towards realizing GS26 and further drive global growth.

 

Appendix: Executive Officers (As of April 1, 2022)

■Group Executive Officer: GEO

Group Managing Executive Officer: GMEO

[Chairman of the Board]

Toshiaki Takagi

 

[President and CEO] 

Shinjiro Sato

 

[Company President]

Group Senior Managing Executive Officer Hikaru Samejima

Medical Care Solutions Company

Group Senior Managing Executive Officer Toshihiko Osada 

Cardiac and Vascular Company

Group Managing Executive Officer Antoinette Gawin

Blood and Cell Technologies Company

[Corporate Functions]

Group Senior Managing Executive Officer Shoji Hatano  
Group Managing Executive Officer Kyo Nishikawa

Chief Human Resources Officer (CHRO)

Group Managing Executive Officer Kazunori Hirose

Chief Manufacturing Officer (CMO)

Group Managing Executive Officer Fumihisa Hirose

General Manager, Strategic Planning Dept. and Chief Technology Officer (CTO)

Group Executive Officer: GEO

[CEOs of Major Business Subsidiaries]

Group Executive Officer James Rushworth

President and CEO, Terumo Medical Corp.

Group Executive Officer Robert DeRyke

President and CEO, Terumo Cardiovascular Systems Corp.

Group Executive Officer Carsten Schroeder

President and CEO, MicroVention, Inc.

Group Executive Officer Erik Pomp

President and CEO, Terumo Aortic

[Regional Representative]

Group Executive Officer Hiroshi Nagumo

Regional Representative, Americas

Group Executive Officer Probir Das

Regional Representative, Asia Pacific and India

Group Executive Officer Norimasa Kunimoto

Regional Representative, Europe, Middle East and Africa

Group Executive Officer Masayuki Maruta

Regional Representative, China

[Corporate Functions]

Group Executive Officer Naoki Muto

Chief Accounting and Financial Officer (CAFO)


■Executive Officer

[Company]

Senior Executive Officer Tsuyoshi Tomita

Division President, Hospital Care Solution Division, Medical Care Solutions Company

Senior Executive Officer Itaru Sakaguchi

Chief Operations Officer (COO), Interventional Systems Division, Cardiac and Vascular Company

President, Terumo Yamaguchi Corp.

Executive Officer Takeshi Kuroo

Senior Vice President, Surgical Business, Cardiac and Vascular Company

General Manager, HeartSheet Business Dept., Cardiac and Vascular Company

Executive Officer Hiroshi Yagi

General Manager, Ashitaka Factory, Interventional Systems Division, Cardiac and Vascular Company

Executive Officer Noritsugu Fujita

Division President, Pharmaceutical Solution Division, Medical Care Solutions Company

[Corporate Functions]

Senior Executive Officer Kazuhisa Senshu

Chief Clinical and Regulatory Affairs Officer (CRAO)

Executive Officer Miho Mizuguchi

Chief Legal Officer (CLO)

Executive Officer Tomoko Manabe

General Manager, Terumo Medical Pranex

Executive Officer Keiji Takeda

General Manager, Human Resources Dept.

Executive Officer Toshio Nakashima

Chief Quality Officer (CQO)

Executive Officer Jin Nishizaki

General Manager, Japan Sales Dept.

Executive Officer Hitoshi Hasegawa

Chief Information Officer (CIO)

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.